万泰生物：全力推进九价HPV疫苗认证，挖掘国际市场机会

Group 1 - The company is actively pursuing WHO PQ certification for its nine-valent HPV vaccine, aiming to expand its global market presence [1] - The company plans to leverage the international achievements of its bivalent HPV vaccine to build a broader global network [1] - The company is exploring long-term opportunities in international markets, including Europe and the United States, while supporting the global strategy to eliminate cervical cancer [1]